Survodutide for weight loss: what the trials actually show

What did @shakia.says.too actually say?

She described going more than 24 hours without eating while on survodutide, saying "I'm literally just not hungry" and forcing herself to eat a croissant and half a quesadilla the previous day. She's also dealing with a headache she suspects is linked to not eating. She's asking her followers what to eat when food sounds completely unappealing. This is not a medical claim so much as a lived experience, but it reflects a real and clinically relevant pattern worth examining.

To be clear: she's not making a bold therapeutic claim here. She's describing genuine discomfort with appetite suppression that's so strong it's become a problem. That's an honest account, and it deserves an honest response rather than a cheerleader reaction from the comments section.

Does the science back this up?

Yes, dramatically reduced appetite is expected with glucagon receptor agonists like survodutide, but going 24-plus hours without meaningful caloric intake is a sign the suppression has tipped into a territory that needs attention, not a badge of honor.

Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor co-agonist in clinical development. Phase 2 data published by Romero-Gómez et al. (2023, The Lancet) showed significant weight loss but also noted that nausea and reduced food intake were among the most common adverse effects, particularly in earlier dose-escalation phases. The glucagon receptor component adds metabolic effects beyond what semaglutide alone produces, including increased energy expenditure, but it also appears to compound appetite suppression in some users.

A headache after prolonged under-eating is consistent with hypoglycemic stress or dehydration, both of which are legitimate physiological responses to caloric restriction. This is not a quirky side effect story. It's a warning sign.

What did they get wrong (or right)?

She got the lived experience right. Survodutide does suppress appetite aggressively, and the pattern she's describing, no hunger signals, food aversion, difficulty identifying anything that sounds edible, matches what clinical trial participants have reported during active dosing phases.

What she's missing, and this matters, is that "not hungry" does not mean "do not need to eat." GLP-1 and glucagon receptor agonists suppress the subjective experience of hunger, but your body's caloric and protein requirements don't pause with them. Jastreboff et al. (2022, NEJM) noted in the tirzepatide trials that patients who restricted intake too aggressively without supervision experienced muscle mass loss alongside fat loss, a ratio problem that undermines long-term metabolic health.

The croissant-plus-half-a-quesadilla day is not a nutrition plan. It's a low-protein, low-micronutrient intake that, repeated consistently, can accelerate lean mass loss. She's not wrong about what she's experiencing. She's just framing it as a dilemma when it's closer to a clinical signal.

What should you actually know?

If you're on survodutide or any GLP-1 class medication and you're regularly going more than 12 to 16 hours without eating, that is not a success metric. It is a side effect pattern that warrants a conversation with a prescribing clinician about dose timing, anti-nausea support, or meal texture and composition strategies.

Protein intake is the first casualty of appetite suppression on these medications. Research from Bikou et al. (2023, Obesity Reviews) found that patients on GLP-1 agonists who did not follow structured protein guidance lost significantly more lean body mass than those who hit minimum protein targets, even at the same calorie deficit.

Practical options when nothing sounds good include high-protein liquid options like Greek yogurt, protein shakes, or bone broth, foods that require minimal preparation and have low sensory intensity. These are not cures for appetite suppression. They're workarounds that keep your body functional while the medication is active. The headache she mentioned is a reasonable prompt to eat something before sleeping, not ignore it.

• Survodutide is still in clinical trials and not FDA-approved as of this writing.
• Compounded versions available through some telehealth channels are not equivalent to trial-grade formulations.
• Persistent appetite suppression severe enough to cause under-eating for 24-plus hours should be reported to your prescriber.

The bottom line

She's describing a real side effect clearly and without exaggeration. The problem is the comments section will tell her this is great progress, and that framing can push people to normalize a pattern that needs clinical management, not social media validation. Extreme appetite suppression on GLP-1 class drugs is not a goal. It is a complication.